Advancing Science. Improving Connections.

Next-generation transdermal cannabinoid therapeutics to improve the lives of patients affected by rare and near-rare neuropsychiatric conditions.

Focusing on the unmet medical needs of patients with rare disorders and their families

Progressing our mission to improve the lives of patients battling certain rare and near-rare diseases

Pioneering cannabinoid treatments for neuropsychiatric conditions

Latest News

05.08

Zynerba Pharmaceuticals Reports First Quarter 2019 Financial Results and Operational Highlights

05.06

Zynerba Pharmaceuticals Receives Fast Track Designation for Zygel™ for the Treatment of Behavioral Symptoms Associated with Fragile X Syndrome (FXS)

04.02

Zynerba Pharmaceuticals to Present at the 2019 H.C. Wainwright Global Life Sciences Conference

03.11

Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2018 Financial Results and Operational Highlights